Price movement over the last 24 hours
Alcon AG vs Marvell Technology Inc — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Marvell Technology Inc trades at $234.01 (market cap $202.28B). The key difference: Marvell Technology Inc is far larger — about 6.2× Alcon AG's market cap, and Alcon AG pays the higher dividend (0.54%). Which is the better fit depends on your goals.
| ALC | MRVL | |
|---|---|---|
Market Cap | $32.69B | $202.28B |
Sector | Health | Technology |
52-Week High | $92.22 | $316.43 |
52-Week Low | $62.02 | $62.31 |
Enterprise Value | $36.28B | $203.71B |
Dividend Yield | 0.54% | 0.1% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Marvell Technology (MRVL) trades at $230.7, down 5.95% amid a sector-wide chip stock selloff. The stock shows strong earnings beats in recent quarters but faces high valuation multiples with a P/E of 85.7 and P/S of 25.0. Technical indicators are neutral, with support near $234 and resistance at $257. Revenue growth is projected to surge to $8.7B in 2026, with net income turning positive to $2.5B, signaling a potential fundamental turnaround.
Outlook: MRVL's AI infrastructure growth and analyst consensus target of $262.6 offer upside, but high valuations and margin pressures pose risks. Investor sentiment is mixed due to semiconductor volatility, though institutional backing remains strong with 82% buy ratings.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →